Skip to main content

Advertisement

SpringerLink
Log in

Systemic Treatment for Noninfectious Intraocular Inflammation

  • Ocular Infections (B Jeng and L Schocket, Section Editors)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

Background

Although uncommon, uveitis and other ocular inflammatory disorders may pose a serious threat to a patient’s vision and quality of life.

Purpose

The purpose of this review is to evaluate the indications for immunosuppressive therapy in the treatment of uveitis and to appraise the data regarding their usage, including efficacy and potential side effects.

Recent Findings

While some agents such as antimetabolites have been used to treat uveitis for decades, there are now newer medications such as biologics that have recently met with great success. Adalimumab is the first biologic therapy FDA approved for the treatment of uveitis.

Summary

There are multiple immunosuppressive therapies available for the treatment of uveitis that allow for sustained control of ocular inflammation and limitation of systemic corticosteroid exposure. Additional research will be necessary to characterize the efficacy of newer agents to determine if they may be superior and tolerated as older therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •of importance

  1. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chang JHM, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm. 2002;10:263–79.

    Article  PubMed  Google Scholar 

  3. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61–98.

    Article  CAS  PubMed  Google Scholar 

  4. Sherif Z, Pleyer U. Corticosteroids in ophthalmology: past-present-future. Ophthalmologica. 2002;216:305–15.

    Article  PubMed  Google Scholar 

  5. Lightman S, Kok H. Developments in the treatment of uveitis. Expert Opin Investig Drugs. 2002;11:59–67.

    Article  PubMed  Google Scholar 

  6. del Rincón I, Inmaculada DF, Battafarano JF, Erikson JM. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthr Rheumatol. 2014;66(21):264–72.

    Article  Google Scholar 

  7. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol. 1991;18:1307–12.

    CAS  PubMed  Google Scholar 

  8. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764–70.

    Article  PubMed  Google Scholar 

  9. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.

    Article  CAS  PubMed  Google Scholar 

  10. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol. 2005;140(1):45–51.

    Article  PubMed  Google Scholar 

  11. Leder HA, Galor A, Thorne JE, Jabs DA. Disappearance of classic birdshot spots after immunosuppression with tacrolimus and mycophenolate mofetil. Br J Ophthalmol. 2008;92(2):291.

    Article  CAS  PubMed  Google Scholar 

  12. Thorne JE, Wittenberg S, Jabs DA, Peters GB, Reed TL, Kedhar SR, Dunn JP. Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology. 2006;113(12):2310–6.

    Article  PubMed  Google Scholar 

  13. Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA. Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol. 2005;140(4):674–8.

    Article  PubMed  Google Scholar 

  14. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32. e1-2

    Article  CAS  PubMed  Google Scholar 

  15. Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology. 2008;115(12):2146–52.

    Article  PubMed  Google Scholar 

  16. Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology. 2013;120(1):186–92.

    Article  PubMed  Google Scholar 

  17. Moradi A, Stroh IG, Reddy AK, Hornbeak DM, Leung TG, Burkholder BM, Thorne JE. Risk of hypotony in juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol. 2016;169:113–24.

    Article  PubMed  Google Scholar 

  18. Nussenblatt RB, and Whitcup SM, Uveitis: Fundamentals and Clinical Practice 4th ed. 2010; Chapter 26, p 332–354.

  19. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993;136:5–28.

    Article  CAS  PubMed  Google Scholar 

  20. Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2006;244:788–94.

    Article  CAS  PubMed  Google Scholar 

  21. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352:35–6.

    Article  CAS  PubMed  Google Scholar 

  22. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;218:222–8.

    Google Scholar 

  23. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003;31:487–91.

    Article  PubMed  Google Scholar 

  24. Zierhut M, Stübiger N, Aboalchamat W, et al. Immunosuppressive treatment with mycophenolate mofetil (CellCept) in the therapy of uveitis. Ophthalmologe. 2001;98:647–51.

    Article  CAS  PubMed  Google Scholar 

  25. Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters 3rd GB, Thorne JE. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2009;115(10):1826–32.

    Article  Google Scholar 

  26. Konstantopoulou M, Belgi A, Griffiths K, Seale J, Macfarlane A. Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. Br Med J. 2005;330:350–1.

    Article  CAS  Google Scholar 

  27. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990;322:281–5.

    Article  CAS  PubMed  Google Scholar 

  28. Vianna RN, Ozdal PC, Deschenes J, Burnier Jr MN. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can J Ophthalmol. 2006;41:183–9.

    Article  PubMed  Google Scholar 

  29. Moore CE. Sympathetic ophthalmitis treated with azathioprine. Br J Ophthalmol. 1968;52:688–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm. 2005;13:289–93.

    Article  PubMed  Google Scholar 

  31. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112:1066–71.

    Article  PubMed  Google Scholar 

  32. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87–90.

    Article  CAS  PubMed  Google Scholar 

  33. Rao NA. Treatment of Vogt-Koyanagi- Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14:71–2.

    Article  PubMed  Google Scholar 

  34. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Suhler EB. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.

    Article  CAS  PubMed  Google Scholar 

  36. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98. e1

    Article  PubMed  PubMed Central  Google Scholar 

  37. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–65.

    Article  PubMed  Google Scholar 

  38. Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146(6):802–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370–7.

    Article  PubMed  Google Scholar 

  40. Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–84.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–6.

    Article  PubMed  Google Scholar 

  42. • Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96. Summary of data regarding the use of biologics in the treatment of ocular inflammatory disease and recommendations as to when to use these drugs as either first- or second-line therapy.

    Article  PubMed  Google Scholar 

  43. Murray PI, Sivaraj RR. Anti-TNF-alpha therapy for uveitis: Behcet and beyond. Eye (Lond). 2005;19:831–3.

    Article  CAS  Google Scholar 

  44. Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:3034–41.

    Article  PubMed  Google Scholar 

  45. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20:155–7.

    Article  CAS  PubMed  Google Scholar 

  46. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat. 2004;15:280–94.

    Article  CAS  PubMed  Google Scholar 

  47. • Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–43. Evidence from the VISUAL I controlled clinical trial demonstrating efficacy of adalimumab for the treatment of active intermediate, posterior and panuveitis.

    Article  CAS  PubMed  Google Scholar 

  48. • Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–92. Evidence from the VISUAL II controlled clinical trial demonstrating efficacy of adalimumab as a corticosteroid-sparing medication among patients with inactive intermediate, posterior or panuveitis and treated with corticosteroids.

    Article  CAS  PubMed  Google Scholar 

  49. Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014 Dec;53(12):2223–31.

    Article  Google Scholar 

  50. Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21(6):468–74.

    Article  CAS  PubMed  Google Scholar 

  51. Okada AA, Goto H, Ohno S, Mochizuki M. Ocular Behcet’s disease research group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592–8.

    Article  CAS  PubMed  Google Scholar 

  52. Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet’s disease. Ocul Immunol Inflamm. 2012;20(3):198–202.

    Article  CAS  PubMed  Google Scholar 

  53. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317–23.

    Article  PubMed  Google Scholar 

  54. Zannin ME, Birolo C, Gerioni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol. 2013;40(1):74–9.

    Article  CAS  PubMed  Google Scholar 

  55. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–4.

    Article  PubMed  Google Scholar 

  56. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitisassociated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  57. Calvo-Rio V, Blanco R, Santos-Gomez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  58. Tomkins-Netzer O, Taylor SRJ, Lightman S. Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmologica. 2013;230:109–15.

    Article  CAS  PubMed  Google Scholar 

  59. Freidlin J, Wong IG, Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol. 2007;91:1414.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Albert M, Beltran E, Martinez-Costa L. Rituximab in rheumatoid arthritis-associated peripheral ulcerative keratitis (in Spanish). Arch Soc Esp Oftalmol. 2011;86:118–20.

    Article  CAS  PubMed  Google Scholar 

  61. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009;60:1540–7.

    Article  PubMed  Google Scholar 

  62. Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, Denisova RV, Chistyakova EG. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163–72.

    Article  PubMed  Google Scholar 

  63. Narvaez J, Diaz-Torne C, Juanola X, Geli C, Llobet JM, Nolla JM, Diaz-Lopez C. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68:607–8.

    Article  CAS  PubMed  Google Scholar 

  64. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology. 2011;50:1390–4.

    Article  CAS  PubMed  Google Scholar 

  65. Baslund B, Wiencke AK, Rasmussen N, Faurschou M, Toft PB. Treatment of orbital inflammation with rituximab in Wegener's granulomatosis. Clin Exp Rheumatol. 2012;30:S7–S10.

    PubMed  Google Scholar 

  66. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD, USA

    Irfan Khan, Ashvini K. Reddy & Jennifer E. Thorne

  2. Division of Ocular Immunology, Wilmer Eye Institute, 600 North Wolfe Street, Woods 476, Baltimore, MD, 21287, USA

    Irfan Khan

  3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD, USA

    Jennifer E. Thorne

Authors
  1. Irfan Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashvini K. Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer E. Thorne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irfan Khan.

Ethics declarations

Conflict of Interest

Irfan Khan declares no conflict of interest. Jennifer Thorne reports grants and personal fees from AbbVie, grants from NEI, during the conduct of the study, grants from Allergan, Inc., grants from NightstaRx, and personal fees from Gilead, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Ocular Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khan, I., Reddy, A.K. & Thorne, J.E. Systemic Treatment for Noninfectious Intraocular Inflammation. Curr Ophthalmol Rep 5, 98–105 (2017). https://doi.org/10.1007/s40135-017-0127-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-017-0127-2

Keywords

Search

Navigation